Controllable degradation gastric swelling sponge as well as preparation method and application thereof

Abstract

The invention relates to controllable degradation gastric swelling sponge as well as a preparation method and application thereof. The controllable degradation gastric swelling sponge structurally comprises N-hydroxysuccinimide active ester groups at two ends of amino albumin substituted polyethylene glycol disuccinimide succinate. Aiming at the problems of mismatching of expansion-degradation rhythm with pet gastrointestinal tract physiology, large one-time administration volume, insufficient mechanical strength, uncontrollable degradation products and the like in the prior art, the invention provides a controllable degradation microsphere which can be rapidly expanded, continuously occupied and punctually disintegrated in the pet stomach. 4-8 h of satiety can be generated through single-time low-dose oral administration, and no residue is discharged within 24 h.

Description

Technical Field

[0001] This invention relates to the field of pet functional food technology, and in particular to a controllable degradable gastric swelling sponge, its preparation method, and its application. Background Technology

[0002] Currently, with the continuous improvement of people's living standards and changes in family structure, more and more families in my country are keeping pets. However, excessive pampering and indiscriminate feeding of pets, coupled with the lack of exercise for pets kept in apartments, have led to a growing problem of pet obesity. Pet obesity has become a top health issue for pets. Obesity is a condition in which energy intake exceeds energy expenditure, resulting in excessive accumulation of body fat. Excess fat not only accumulates under the skin, making pets intolerant to heat, clumsy, and easily fatigued, but it can also cause various diseases, including heart disease, diabetes, arthritis, herniated discs, and fractures. Therefore, maintaining the health of pets and controlling their weight is extremely important.

[0003] To address the aforementioned issues, research is currently underway on gastric swelling sponges that rapidly absorb water and swell upon entering a pet's stomach, generating a feeling of fullness and undergoing controlled degradation within a predetermined timeframe, aiming to promote weight loss in pets. As research progresses, two main weight loss strategies have emerged: mechanically occupies space and hydrogel microspheres. For example, CN114699382A discloses a pH-sensitive glucomannan gastric weight loss material that occupies the gastric cavity through water absorption and swelling. However, it requires the simultaneous administration of a pH adjuster to initiate degradation, making the process complex, and the adaptability of glucomannan to the acidic gastric environment of dogs and cats has not been confirmed. CN105815363A describes edible polymer hydrogel microspheres that can swell in the stomach, but their design is tailored to the human stomach. The rhythm of swelling-collapse-re-swelling is coupled with small intestinal emptying. Since the gastrointestinal motility cycle of pets differs significantly from that of humans, the retention time is difficult to predict, and a clear degradation timeframe is not provided.

[0004] The two weight loss strategies mentioned above have the following problems: the degradation behavior does not match the pet's gastric pH (1.5-3.5) and gastric emptying rhythm (about 2-8 hours for dogs and 2-6 hours for cats), which leads to the prolonged retention of the capsules, causing vomiting or premature expulsion and loss of weight loss effect; in order to obtain sufficient volume, multiple capsules often need to be swallowed at one time, which increases the pet's resistance; the degradation products have a wide molecular weight distribution, and there is no data to support whether long-term continuous use will result in intestinal accumulation.

[0005] Based on the current problems, there is an urgent need for a gastric swelling sponge that can expand at a high rate and is self-degradable, which is a technical problem that needs to be solved in the current management of pet obesity. Summary of the Invention

[0006] To address the aforementioned technical problems, this invention provides a controllable degradable gastric swelling sponge, its preparation method, and its application. Addressing issues such as the mismatch between the expansion-degradation rhythm and the physiology of the pet's gastrointestinal tract, large single-dose volume, insufficient mechanical strength, and uncontrollable degradation products in existing technologies, this invention provides a controllable degradable sponge that can "rapidly expand, continuously occupy space, and disintegrate on time" in the pet's stomach. This allows for a feeling of fullness for 4-8 hours with a single low-dose oral administration, with no residue excreted within 24 hours.

[0007] To achieve this objective, the present invention adopts the following technical solution:

[0008] In a first aspect, the present invention provides a controllable degradable gastric swelling sponge, wherein the structure of the controllable degradable gastric swelling sponge comprises an amino albumin-substituted N-hydroxysuccinimide active ester at both ends of polyethylene glycol disuccinimide succinate.

[0009] In this invention, amino albumin and polyethylene glycol disuccinimide succinate are used as ABSA-PEG-SS sponges. After the sponge is prepared, it is compressed to 1 / 10 of its volume under high pressure due to its excellent mechanical properties. After contact with gastric juice, the sponge can rapidly expand to its initial volume before compression within 5 minutes. The double-arm PEG-succinamide ester crosslinking chain cleaves precisely at pH 2-4 for 2-12 hours. The double network loses strength synchronously and disintegrates with zero fragments. The product consists entirely of absorbable amino acids and low molecular weight PEG, with no residue and no granulation. Mass production can be achieved in one step of freeze-drying-crosslinking. This provides a safe, adjustable, and high-margin controllable degradation solution for "instant expansion-occupancy-precise point" in the pet's stomach.

[0010] Preferably, the side-chain amino groups of the amino albumin are linked to polyethylene glycol disuccinimide succinate via amide bonds.

[0011] Preferably, the structure of the controllable degradable gastric swelling sponge includes the structure shown in Formula I:

[0012]

[0013] Formula I: Structural formula for the chemical synthesis of sponges

[0014] Where X is aminoalbumin, and n is in the range of 135-138; where 135-138 can be, for example, 135, 136, 137 or 138, etc.

[0015] Secondly, the present invention provides a method for preparing a controllable degradable gastric swelling sponge, the method comprising mixing amino albumin and polyethylene glycol disuccinimide succinate.

[0016] Preferably, the preparation method includes mixing and solidifying an amino albumin solution and a polyethylene glycol disuccinimide succinate solution, followed by freezing and drying to obtain the final product.

[0017] In this invention, two solutions are mixed and then freeze-dried to prepare a controllable degradable gastric swelling sponge. This operation is simple, requires little technical expertise, and is conducive to industrial production.

[0018] Preferably, the mass ratio of polyethylene glycol disuccinimide succinate to amino albumin is 1:(1~2). The (1~2) can be, for example, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9 or 2, etc.

[0019] In this invention, controllable degradable gastric swelling sponges can be effectively constructed within the above-mentioned range. Exceeding this range will cause the network to collapse after freeze-drying or fail to form sponge precursors, ultimately making it unsuitable for compression to form oral sponges.

[0020] Preferably, the method for preparing the aminoalbumin solution includes dissolving aminoalbumin in buffer 1.

[0021] Preferably, the pH value of the buffer solution 1 is 8 to 10. For example, it can be 8, 8.5, 9, 9.5 or 10, etc.

[0022] Preferably, the buffer solution 1 comprises a phosphate buffer solution.

[0023] Preferably, the concentration of the aminoalbumin solution is 15% to 20%. The 15% to 20% can be, for example, 15%, 16%, 17%, 18%, 19%, or 20%.

[0024] Preferably, the method for preparing the polyethylene glycol disuccinimide succinate solution includes dissolving polyethylene glycol disuccinimide succinate in buffer solution 2.

[0025] Preferably, the pH value of the buffer solution 2 is 6 to 8. For example, it can be 6, 6.5, 7, 7.5 or 8, etc.

[0026] Preferably, the buffer solution 2 comprises a phosphate buffer solution.

[0027] Preferably, the concentration of the polyethylene glycol disuccinimide succinate solution is 10% to 20%. For example, it can be 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20%.

[0028] Preferably, the cryogenic freezing temperature is -90℃ to -70℃, and the time is 20 to 30 hours. The -90℃ to -70℃ range can be, for example, -70℃, -75℃, -80℃, -85℃, or -90℃. The 20 to 30 hours can be, for example, 20 hours, 22 hours, 24 hours, 26 hours, 28 hours, or 30 hours.

[0029] Preferably, the drying temperature is -80 to -70°C, and the drying time is 36 to 60 hours. The 36 to 60 hours can be, for example, 36 hours, 40 hours, 45 hours, 50 hours, 55 hours, or 60 hours. The -80°C to -70°C can be, for example, -70°C, -72°C, -74°C, -76°C, -78°C, or -80°C.

[0030] Preferably, the preparation method further includes tableting.

[0031] In this invention, to reduce pets' resistance, the prepared controllable degradable gastric swelling sponge can be compressed into small tablets. The compressed volume is significantly reduced, making it easier for pets to swallow. Furthermore, due to the high processability of the sponge, appropriate pet-safe additives can be added according to the pet's type, making it easier for pets to take it willingly.

[0032] Thirdly, the present invention provides an application of the controllable degradable gastric swelling sponge according to the first aspect or the method for preparing the controllable degradable gastric swelling sponge according to the second aspect in promoting weight loss in pets.

[0033] Compared with the prior art, the present invention has at least the following beneficial effects:

[0034] This invention uses two safe reagents to prepare a controllable degradable gastric swelling sponge, which can expand in the pet's stomach to fill the stomach and increase the feeling of fullness. It remains swollen in the body for 8-12 hours, and then gradually degrades, completely degrading within 24 hours so as to be excreted from the body, thus not affecting the next feeding cycle. Attached Figure Description

[0035] Figure 1 This is the NMR spectrum of polyethylene glycol disuccinimide succinate.

[0036] Figure 2 This is a schematic diagram of the reaction between polyethylene glycol disuccinimide succinate and amino albumin.

[0037] Figure 3 The NMR spectrum is for polyethylene glycol disuccinimide glutarate.

[0038] Figure 4 This is an in vitro swelling curve of the gastric swelling sponge from Example 1.

[0039] Figure 5 This is an in vitro swelling diagram of the gastric swelling sponge from Example 1.

[0040] Figure 6 This is a shape adaptation diagram for Example 1.

[0041] Figure 7 The images show the surface morphology of Examples 1, 4, 6 and 8.

[0042] Figure 8 The images show the hemolysis experiments in Examples 1-3. Detailed Implementation

[0043] The technical solution of the present invention will be further described below with reference to the accompanying drawings and specific embodiments. However, the following examples are merely simplified examples of the present invention and do not represent or limit the scope of protection of the present invention. The scope of protection of the present invention is determined by the claims.

[0044] The sources of reagents used in the following examples are:

[0045] Both polyethylene glycol disuccinimide succinate and amino albumin were prepared in the laboratory.

[0046] Preparation of polyethylene glycol disuccinimide succinate: Two-arm polyethylene glycol with a molecular weight of 6000 Da and succinic anhydride were mixed overnight in anhydrous dichloromethane under the catalysis of 4-dimethylaminopyridine. The reaction mixture was centrifuged three times with 5% (w / w) NaCl solution to remove impurities. Anhydrous magnesium sulfate was added to remove residual water. The reaction mixture was precipitated with petroleum ether, then rotary evaporated and dried under vacuum. This yielded white, blocky carboxyl-terminated polyethylene glycol. Subsequently, the carboxyl-terminated polyethylene glycol and N-hydroxysuccinimide (NHS) were mixed overnight in anhydrous dichloromethane under the catalysis of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC). The above steps were repeated to obtain a white powder, Bi-PEG-SS.

[0047] Preparation of amino albumin: The carboxyl groups on the surface of albumin were activated in situ using EDC, condensed with a large amount of ethylenediamine, reacted at room temperature for 12 h, and then lyophilized by dialyzing; an additional primary amino group was introduced in one step, with a yield >90%.

[0048] Example 1

[0049] The controllable degradable gastric swelling sponge prepared in this embodiment

[0050] (1) Solution preparation

[0051] Aminoalbumin solution: Dissolve 0.15 g of aminoalbumin (ABSA) in phosphate buffer solution with a pH of 9 to achieve a final concentration of 15%.

[0052] Polyethylene glycol disuccinimide succinate solution: Dissolve 0.1 g of polyethylene glycol disuccinimide succinate (Bi-PEG-SS) in phosphate buffer solution with a pH of 7 to a final concentration of 10%. The average number of repeating structures (n) in polyethylene glycol disuccinimide succinate is 136.

[0053] (2) Sponge preparation

[0054] The amino albumin solution and polyethylene glycol disuccinimide succinate solution were mixed and poured into a mold. After the material solidified, it was frozen at -80°C for 24 hours, and then dried at -80°C for 48 hours using a low-temperature freeze dryer. The dried sponge was then stored at room temperature.

[0055] Example 2

[0056] The controllable degradable gastric swelling sponge prepared in this embodiment

[0057] (1) Solution preparation

[0058] Aminoalbumin solution: Dissolve 0.1 g of aminoalbumin (ABSA) in phosphate buffer solution with a pH of 9 to achieve a final concentration of 10%.

[0059] Polyethylene glycol disuccinimide succinate solution: Dissolve 0.1 g of polyethylene glycol disuccinimide succinate (Bi-PEG-SS) in phosphate buffer solution with a pH of 7 to a final concentration of 10%. The average number of repeating structures (n) in polyethylene glycol disuccinimide succinate is 138.

[0060] (2) Sponge preparation

[0061] The amino albumin solution and polyethylene glycol disuccinimide succinate solution were mixed and poured into a mold. After the material solidified, it was frozen at -70°C for 30 hours, and then dried at -80°C for 36 hours using a low-temperature freeze dryer. The dried sponge was then stored at room temperature.

[0062] Example 3

[0063] The controllable degradable gastric swelling sponge prepared in this embodiment

[0064] (1) Solution preparation

[0065] Aminoalbumin solution: Dissolve 0.3 g of aminoalbumin (ABSA) in phosphate buffer solution with a pH of 9 to achieve a final concentration of 20%.

[0066] Polyethylene glycol disuccinimide succinate solution: Dissolve 0.1 g of polyethylene glycol disuccinimide succinate (Bi-PEG-SS) in phosphate buffer solution with a pH of 8 to a final concentration of 10%. The average number of repeating structures (n) in polyethylene glycol disuccinimide succinate is 135.

[0067] (2) Sponge preparation

[0068] The amino albumin solution and polyethylene glycol disuccinimide succinate solution were mixed and poured into a mold. After the material solidified, it was frozen at -90°C for 20 hours, and then dried at -80°C for 60 hours using a low-temperature freeze dryer. The dried sponge was then stored at room temperature.

[0069] Example 4

[0070] The controllable degradable gastric swelling sponge prepared in this embodiment differs from that in Example 1 only in that the mass ratio of polyethylene glycol disuccinimide succinate to amino albumin is 1:0.5; otherwise, it is the same as that in Example 1.

[0071] Example 5

[0072] The controllable degradable gastric swelling sponge prepared in this embodiment differs from that in Example 1 only in that the mass ratio of polyethylene glycol disuccinimide succinate to amino albumin is 1:2.5; otherwise, it is the same as that in Example 1.

[0073] Example 6

[0074] The controllable degradable gastric swelling sponge prepared in this embodiment differs from that in Example 1 only in that the concentration of the polyethylene glycol disuccinimide succinate solution is 25%, while the rest is the same as in Example 1.

[0075] Example 7

[0076] The controllable degradable gastric swelling sponge prepared in this embodiment differs from that in Example 1 only in that the concentration of the polyethylene glycol disuccinimide succinate solution is 30%, while the rest is the same as in Example 1.

[0077] Example 8

[0078] The controllable degradable gastric swelling sponge prepared in this embodiment differs from that in Example 1 only in that the concentration of amino albumin is 3%, while the rest is the same as in Example 1.

[0079] Example 9

[0080] The controllable degradable gastric swelling sponge prepared in this embodiment differs from that in Example 1 only in that the concentration of amino albumin is 5%, while all other aspects are the same as in Example 1.

[0081] Example 10

[0082] The controllable degradable gastric swelling sponge prepared in this embodiment differs from that in Example 1 only in that the average number of repeating structures n in polyethylene glycol disuccinimide succinate is 44, while the rest is the same as in Example 1.

[0083] Example 11

[0084] The controllable degradable gastric swelling sponge prepared in this embodiment differs from that in Example 1 only in that the average number of repeating structures n in polyethylene glycol disuccinimide succinate is 225, while the rest is the same as in Example 1.

[0085] Comparative Example 1

[0086] The controllable degradable gastric swelling sponge prepared in this comparative example differs from Example 1 only in that it uses only ordinary bovine serum albumin; otherwise, it is identical to Example 1.

[0087] Comparative Example 2

[0088] The controllable degradable gastric swelling sponge prepared in this comparative example differs from Example 1 only in that amino albumin is replaced with gelatin; otherwise, it is identical to Example 1.

[0089] Comparative Example 3

[0090] The controllable degradable gastric swelling sponge prepared in this comparative example differs from Example 1 only in that polyethylene glycol disuccinimide glutarate is replaced with polyethylene glycol disuccinimide succinate, which is consistent with Example 1.

[0091] Comparative Example 5

[0092] The controllable degradable gastric swelling sponge prepared in this comparative example differs from Example 1 only in that it uses a commercially available sponge; otherwise, it is identical to Example 1.

[0093] Test Example 1

[0094] This test case underwent MRI detection.

[0095] The polyethylene glycol disuccinimide succinate used in this test example was subjected to NMR analysis. Its specific structure is shown below. Figure 1 As shown, after mixing the above-mentioned polyethylene glycol disuccinimide succinate with amino albumin, the amino albumin replaces the NHS groups at both ends of the polyethylene glycol disuccinimide succinate, such as... Figure 2 As shown.

[0096] The comparative example used polyethylene glycol disuccinimide glutarate was analyzed by NMR, and its specific structure is shown below. Figure 3 As shown.

[0097] Test Example 2

[0098] This test case is used to detect the swelling effect.

[0099] This embodiment verifies the above facts and compares the in vitro swelling experiment with the comparative example. Polyethylene glycol disuccinimide succinate and amino albumin were used to prepare a sponge according to the conditions of Example 1. The freeze-dried sponge was weighed as dry weight (Wd), and then soaked in 40 mL of PBS at 37°C. The sponge was removed periodically, and the surface water was absorbed with filter paper; the wet weight (Wt) was then measured. The swelling degree was reflected by the percentage of remaining mass, specifically calculated according to the following formula:

[0100] Remaining mass percentage (%) = (Wt – Wd) / Wd × 100%.

[0101] The specific results are shown in Table 1.

[0102] Table 1

[0103]

[0104] The results above show that:

[0105] (1) By comparing Example 1 with Examples 2-3, it can be seen that the controllable degradable gastric swelling sponge prepared by the present invention can expand its volume and increase the feeling of fullness without high-pressure compression treatment, such as Figure 4 As shown, it swells and remains in the body for 8-12 hours, then gradually degrades, and is completely degraded within 24 hours, without affecting the pet's feeding in the next cycle. Figure 5 As shown, after being immersed in simulated gastric fluid in vitro for 3 minutes following high-pressure compression treatment, the ABSA-SS sponge can swell to 6 times its own volume, and the volume continues to increase.

[0106] Furthermore, ABSA-SS foam has excellent shape adaptability, can be fabricated into various desired shapes, and remains stable within this structure. For example... Figure 6 As shown, the prepared cylindrical and square sponges can still maintain their shape to fit the mold after demolding.

[0107] (2) By comparing Example 1 with Examples 4-5, it can be seen that both excessively high and low amino albumin content will affect the overall solid content of the sponge and thus affect chemical cross-linking, ultimately leading to a prolonged or shortened degradation time.

[0108] (3) By comparing Example 1 with Examples 6-9, it can be seen that the concentration of polyethylene glycol disuccinimide succinate is too high, which leads to stronger chemical cross-linking and a denser cross-linking network, which is not conducive to the degradation of the sponge in about 24 hours; the lower the concentration of amino albumin, the weaker the chemical cross-linking and the looser the cross-linking network, resulting in a shorter sponge degradation time.

[0109] (4) By comparing Example 1 with Examples 10-11, it can be seen that the change in the degree of polymerization of polyethylene glycol will affect the change in the crosslinking density of the final sponge and ultimately affect the swelling-degradation coupling. Although high molecular weight polyethylene glycol expands greatly, the long chain entanglement will delay the breakage of the polymer main chain.

[0110] (5) By comparing Example 1 with Comparative Examples 1-3, it can be seen that different chemical reaction substrates are closely related to the degradation time of the sponge. However, whether it is bovine serum albumin, gelatin to replace amino albumin, or polyethylene glycol disuccinimide glutarate to replace polyethylene glycol disuccinimide succinate, the degradation time exceeds 24 hours and cannot achieve the ideal body content state.

[0111] (6) The comparison between Example 1 and Comparative Example 4 shows that some commercially available gelatin-glutaraldehyde sponges cannot meet the ideal requirements for adapting to the gastrointestinal motility cycle of pets. In contrast, ABSA-SS sponges can degrade in a short period of time and continue to expand to a relatively large volume.

[0112] Test Example 3

[0113] This test case is used to test mechanical properties.

[0114] The surface morphology of the sponges from Examples 1, 4, 6, and 8 was observed using scanning electron microscopy. Figure 7 As shown, the sponge prepared in Example 1 had a dense surface and ideal cross-linking effect. However, the sponge structures in Examples 4, 6, and 8 were either too loose or too dense, which was not conducive to further high-pressure compression treatment.

[0115] Test Example 4

[0116] This embodiment involves a safety experiment.

[0117] The sponges from Examples 1-3 were subjected to in vitro hemolysis experiments to verify the biocompatibility of the modified representative components. Figure 8 As shown, the experimental results indicate that the hemolysis rate in all example groups was less than 5%, which meets the evaluation criteria for blood compatibility of biomaterials.

[0118] In summary, this invention addresses the problems of existing technologies, such as the mismatch between the expansion-degradation rhythm and the physiology of the pet's gastrointestinal tract, large single-dose volume, insufficient mechanical strength, and uncontrollable degradation products. It provides a controllable degradable microsphere that can "rapidly expand, continuously occupy space, and disintegrate on time" in the pet's stomach. Additives can be flexibly added for different pets to encourage them to eat actively. A single low-dose oral administration can produce a feeling of fullness for 4-8 hours, with no residue excreted within 24 hours.

[0119] The applicant declares that the above description is only a specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Those skilled in the art should understand that any changes or substitutions that can be easily conceived by those skilled in the art within the technical scope disclosed in the present invention fall within the protection and disclosure scope of the present invention.

Claims

1. A controllable degradable gastric swelling sponge, characterized in that, The structure of the controllable degradable gastric swelling sponge includes amino albumin replacing the N-hydroxy succinimide active ester groups at both ends of polyethylene glycol disuccinimide succinate.

2. The controllable degradable gastric swelling sponge according to claim 1, characterized in that, The amino group on the side chain of the amino albumin is linked to polyethylene glycol disuccinimide succinate via an amide bond.

3. The controllable degradable gastric swelling sponge according to claim 1 or 2, characterized in that, The structure of the controllable degradable gastric swelling sponge is shown in Formula I: Formula I; Where X is aminoalbumin, and n ranges from 135 to 138.

4. A method for preparing a controllable degradable gastric swelling sponge according to any one of claims 1-3, characterized in that, The preparation method includes mixing amino albumin and polyethylene glycol disuccinimide succinate.

5. The method for preparing the controlled-degradation gastric swelling sponge according to claim 4, characterized in that, The preparation method includes mixing and solidifying an amino albumin solution and a polyethylene glycol disuccinimide succinate solution, followed by low-temperature freezing and drying.

6. The method for preparing the controlled-degradation gastric swelling sponge according to claim 5, characterized in that, The mass ratio of polyethylene glycol disuccinimide succinate to amino albumin is 1:(1~2).

7. The method for preparing the controlled-degradation gastric swelling sponge according to claim 5 or 6, characterized in that, The method for preparing the aminoalbumin solution includes dissolving aminoalbumin in buffer 1; Preferably, the pH value of the buffer solution 1 is 8-10; Preferably, the buffer solution 1 comprises a phosphate buffer solution; Preferably, the concentration of the aminoalbumin solution is 15% to 20%; Preferably, the method for preparing the polyethylene glycol disuccinimide succinate solution includes dissolving polyethylene glycol disuccinimide succinate in buffer solution 2; Preferably, the pH value of the buffer solution 2 is 6-8; Preferably, the buffer solution 2 comprises a phosphate buffer solution; Preferably, the concentration of the polyethylene glycol disuccinimide succinate solution is 10% to 20%.

8. The method for preparing the controlled-degradation gastric swelling sponge according to any one of claims 5-7, characterized in that, The cryogenic freezing temperature is -90℃ to -70℃, and the time is 20 to 30 hours; Preferably, the drying temperature is -80℃ to -70℃, and the drying time is 36 to 60 hours.

9. The method for preparing the controlled-degradation gastric swelling sponge according to any one of claims 4-8, characterized in that, The preparation method also includes tableting.

10. The application of the controllable degradable gastric swelling sponge according to any one of claims 1-3 or the preparation method of the controllable degradable gastric swelling sponge according to any one of claims 4-9 in promoting pet weight loss.

Images